475 related articles for article (PubMed ID: 24225201)
21. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT.
Komajda M; Böhm M; Borer JS; Ford I; Robertson M; Manolis AJ; Tavazzi L; Swedberg K;
Eur J Heart Fail; 2014 Jul; 16(7):810-6. PubMed ID: 24961493
[TBL] [Abstract][Full Text] [Related]
22. Ivabradine for chronic heart failure?
Drug Ther Bull; 2012 Oct; 50(10):117-20. PubMed ID: 23065752
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
Wali RK; Iyengar M; Beck GJ; Chartyan DM; Chonchol M; Lukas MA; Cooper C; Himmelfarb J; Weir MR; Berl T; Henrich WL; Cheung AK
Circ Heart Fail; 2011 Jan; 4(1):18-26. PubMed ID: 21036889
[TBL] [Abstract][Full Text] [Related]
24. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine.
Doesch AO; Celik S; Ehlermann P; Frankenstein L; Zehelein J; Koch A; Katus HA; Dengler TJ
Transplantation; 2007 Oct; 84(8):988-96. PubMed ID: 17989604
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure.
Freeman JV; Yang J; Sung SH; Hlatky MA; Go AS
Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):525-33. PubMed ID: 24021697
[TBL] [Abstract][Full Text] [Related]
26. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
[TBL] [Abstract][Full Text] [Related]
27. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure.
Komajda M; Böhm M; Borer J; Ford I; Krum H; Tase A; Tavazzi L; Swedberg K
Eur J Heart Fail; 2013 Jan; 15(1):79-84. PubMed ID: 22892123
[TBL] [Abstract][Full Text] [Related]
28. Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure.
Reil JC; Robertson M; Ford I; Borer J; Komajda M; Swedberg K; Tavazzi L; Böhm M
Eur J Heart Fail; 2013 Sep; 15(9):1044-52. PubMed ID: 23696612
[TBL] [Abstract][Full Text] [Related]
29. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice.
Di Franco A; Sarullo FM; Salerno Y; Figliozzi S; Parrinello R; Di Pasquale P; Lanza GA
Am J Cardiovasc Drugs; 2014 Apr; 14(2):101-10. PubMed ID: 24327100
[TBL] [Abstract][Full Text] [Related]
30. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
Tondi L; Fragasso G; Spoladore R; Pinto G; Gemma M; Slavich M; Godino C; Salerno A; Montanaro C; Margonato A
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):351-356. PubMed ID: 29762337
[TBL] [Abstract][Full Text] [Related]
31. Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study.
Bagriy AE; Schukina EV; Samoilova OV; Pricolota OA; Malovichko SI; Pricolota AV; Bagriy EA
Adv Ther; 2015 Feb; 32(2):108-19. PubMed ID: 25700807
[TBL] [Abstract][Full Text] [Related]
32. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study.
Borer JS; Böhm M; Ford I; Komajda M; Tavazzi L; Sendon JL; Alings M; Lopez-de-Sa E; Swedberg K;
Eur Heart J; 2012 Nov; 33(22):2813-20. PubMed ID: 22927555
[TBL] [Abstract][Full Text] [Related]
33. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.
Wikstrand J; Wedel H; Castagno D; McMurray JJ
J Intern Med; 2014 Feb; 275(2):134-43. PubMed ID: 24118421
[TBL] [Abstract][Full Text] [Related]
34. Ivabradine: Current and Future Treatment of Heart Failure.
Thorup L; Simonsen U; Grimm D; Hedegaard ER
Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):89-97. PubMed ID: 28371247
[TBL] [Abstract][Full Text] [Related]
35. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K;
Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517
[TBL] [Abstract][Full Text] [Related]
36. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy.
Böhm M; Borer JS; Camm J; Ford I; Lloyd SM; Komajda M; Tavazzi L; Talajic M; Lainscak M; Reil JC; Ukena C; Swedberg K
Eur J Heart Fail; 2015 May; 17(5):518-26. PubMed ID: 25801408
[TBL] [Abstract][Full Text] [Related]
37. Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients.
Rogers JK; Kielhorn A; Borer JS; Ford I; Pocock SJ
Curr Med Res Opin; 2015; 31(10):1903-9. PubMed ID: 26361063
[TBL] [Abstract][Full Text] [Related]
38. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.
Staszewsky L; Wong M; Masson S; Barlera S; Carretta E; Maggioni AP; Anand IS; Cohn JN; Tognoni G; Latini R;
J Card Fail; 2007 Dec; 13(10):797-804. PubMed ID: 18068611
[TBL] [Abstract][Full Text] [Related]
39. Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial.
Bocchi EA; Rassi S; Guimarães GV;
ESC Heart Fail; 2018 Jun; 5(3):249-256. PubMed ID: 29266804
[TBL] [Abstract][Full Text] [Related]
40. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD.
Dransfield MT; Rowe SM; Johnson JE; Bailey WC; Gerald LB
Thorax; 2008 Apr; 63(4):301-5. PubMed ID: 17951276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
